Weekly carboplatin + paclitaxel (CROSS-style chemo backbone)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CARBOPLATIN DRUG-PACLITAXEL |
|---|
| ID | REG-CARBOPLATIN-PACLITAXEL-WEEKLY |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
CROSS protocol concurrent with RT 41.4 Gy / 23 fractions. Both squamous and adeno benefit (CROSS subgroup analyses) with pCR ~25% (squamous higher than adeno). The RT component is NOT modellable in current OpenOnco schema — see PROPOSAL §17. This regimen entry represents the chemo-only backbone; "CROSS" the full modality is free-text on the Indication awaiting proposal ratification.
Used By
Indication
IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT- IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT
Radiation Courses
RC-CROSS-NEOADJ- CROSS neoadjuvant chemoradiation for resectable esophageal cancer
Regimen
REG-CARBO-PACLI-CONCURRENT-RT-ESOPH- Weekly carboplatin + paclitaxel concurrent with definitive RT (esophageal)